Home / Insights / Anti-Amyloid Therapy: Who May Benefit and What Are the Risks?
Treatment
Anti-Amyloid Therapy: Who May Benefit and What Are the Risks?
Anti-amyloid antibodies have changed early Alzheimer’s treatment, but they are not simple infusions for everyone with memory loss. Eligibility depends on disease stage, confirmed amyloid pathology, MRI findings, medical risk, and a realistic understanding of benefit.
10 minute read
What anti-amyloid therapy is designed to do
Amyloid beta accumulates in the brain years before dementia becomes advanced. Lecanemab and donanemab are monoclonal antibodies designed to reduce amyloid pathology. In pivotal trials, both drugs slowed clinical decline compared with placebo in people with early symptomatic Alzheimer’s disease.
That distinction matters: the goal is to slow worsening. These treatments do not cure Alzheimer’s disease, restore lost neurons, or return cognition to baseline.
Key Fact
Anti-amyloid treatment is for selected patients with early symptomatic Alzheimer’s disease — not for every person with memory loss or every person with a positive amyloid biomarker.
Who was studied — and who was not
FDA labeling for both Leqembi (lecanemab) and Kisunla (donanemab) states that treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of Alzheimer’s disease, the populations in which treatment was studied. Amyloid beta pathology must be confirmed before treatment.
There are no equivalent data establishing benefit from starting these drugs in people with moderate or severe dementia. Likewise, a positive amyloid test in someone without symptoms is not automatically an indication for treatment.
Why MRI screening and monitoring are central
The major treatment-specific safety issue is amyloid-related imaging abnormalities, or ARIA. ARIA-E involves edema or fluid-related swelling; ARIA-H involves microhemorrhage or superficial siderosis. Many cases are asymptomatic, but symptoms can include headache, confusion, dizziness, visual changes, nausea, gait difficulty, or focal neurologic symptoms.
Current Leqembi labeling includes MRI monitoring early in treatment and at specified intervals. Donanemab also requires baseline and scheduled MRI monitoring. These protocols exist because clinically important ARIA can be detected before it becomes severe.
What This Means
The decision is not simply “Is the drug available?” It is “Does the expected benefit justify the risk and treatment burden for this particular patient?”
APOE ε4 changes the risk conversation
APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer’s disease. It also influences ARIA risk during anti-amyloid treatment. FDA labeling warns that ARIA incidence is higher in APOE ε4 homozygotes than in heterozygotes and noncarriers.
For that reason, clinicians should discuss APOE testing and what the result could mean before treatment. The test is not simply a yes-or-no eligibility test; it is part of informed risk assessment.
| Question | Why it matters |
|---|---|
| Is the disease at an early symptomatic stage? | That is the stage studied in pivotal trials and reflected in FDA labeling. |
| Is amyloid pathology confirmed? | Required before treatment. |
| What does the baseline MRI show? | Certain findings may increase treatment risk or affect eligibility. |
| What is the APOE ε4 genotype? | Homozygotes have higher ARIA risk; testing informs the discussion. |
| Can the patient complete monitoring? | MRI surveillance and clinical follow-up are part of safe treatment. |
How much benefit should families expect?
Clinical trials showed a slowing in cognitive and functional decline over the study period, not a dramatic improvement. The practical value of that slowing can differ among patients depending on age, baseline function, disease trajectory, treatment burden, and personal goals.
A useful discussion should include absolute expectations: what the trial measured, how large the average difference was, what the treatment does not change, and whether the patient values a potential slowing enough to accept repeated monitoring and treatment risk.
Treatment is becoming more flexible — but not simpler
Lecanemab was initially administered by intravenous infusion. In July 2026, the FDA approved a subcutaneous starting regimen using the Leqembi IQLIK autoinjector, expanding administration options. The availability of a subcutaneous regimen may reduce some infusion burden, but it does not remove the need for amyloid confirmation, MRI surveillance, ARIA risk assessment, and clinical follow-up.
Donanemab is administered intravenously every four weeks under current FDA labeling. Treatment decisions remain individualized and depend on current prescribing information.
When the answer may be “not a good fit”
Some patients may have MRI findings, bleeding risk, anticoagulant-related concerns, advanced disease stage, frailty, or other medical factors that shift the risk-benefit balance. Others may decide that the monitoring burden or modest average benefit does not fit their goals.
Declining anti-amyloid therapy is not the same as declining Alzheimer’s care. Symptom treatment, safety planning, caregiver support, management of sleep and mood, vascular risk reduction, and future planning remain important regardless of anti-amyloid eligibility.
Important Distinction
Declining anti-amyloid therapy is not the same as declining Alzheimer’s care.
Frequently asked questions
Do anti-amyloid drugs cure Alzheimer’s disease?
No. They reduce amyloid pathology and can slow clinical decline in selected patients, but they do not cure the disease.
What is ARIA?
ARIA is a class of MRI-detected brain changes associated with amyloid-targeting antibodies. It can involve edema/swelling or bleeding-related changes and is often asymptomatic, but serious cases can occur.
Can someone with no symptoms take these drugs to prevent Alzheimer’s?
Current FDA indications are based on treatment of Alzheimer’s disease initiated in the mild cognitive impairment or mild dementia stage. Preventive use in asymptomatic people is a separate research question.
The clinical perspective
Anti-amyloid therapy represents genuine progress, but its value depends on precision: the right disease stage, the right biomarker evidence, the right safety profile, and expectations anchored in trial data rather than headlines.
For some patients, slowing decline may be worth the burden and risk. For others, it may not be. That is why these therapies are best understood as shared clinical decisions, not automatic next steps after an Alzheimer’s diagnosis.
Related Insights
How Alzheimer’s Disease Changes the Brain
The amyloid and tau biology behind these treatments. Read more →
Can a Blood Test Detect Alzheimer’s Disease?
How blood biomarkers may support diagnosis and treatment eligibility. Read more →
Is Alzheimer’s Disease Genetic? Understanding APOE and Inherited Risk
Why APOE matters for risk — and for ARIA discussions. Read more →
Selected References
U.S. Food and Drug Administration. LEQEMBI (lecanemab-irmb) Prescribing Information, revised 2026.
U.S. Food and Drug Administration. Supplemental approval for Leqembi IQLIK subcutaneous starting regimen, July 13, 2026.
U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer’s disease (Kisunla/donanemab), 2024.
U.S. Food and Drug Administration. FDA recommends additional, earlier MRI monitoring for patients taking Leqembi, 2025.
van Dyck CH, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388:9–21.
Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512–527.
June/1/2026